Bolt Biotherapeutics, Inc. (BOLT) has a negative trailing P/E of -0.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -379.76%.
Criteria proven by this page:
Overall SharesGrow Score: 54/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -107.8 | 0.00 | -78.39 | 0.00 | - |
| 2019 | -168.9 | 4.56 | -112.34 | 23,955.31 | - |
| 2020 | -383.8 | 8.18 | -222.08 | 100,894.63 | - |
| 2021 | -37.2 | -0.92 | 14.65 | 2,908.87 | - |
| 2022 | -11.0 | 0.63 | 5.66 | 169.54 | - |
| 2023 | -12.2 | 0.60 | 7.51 | 107.54 | - |
| 2024 | -6.5 | 0.66 | 7.14 | 53.13 | - |
| 2025 | -0.3 | 0.00 | 0.39 | 1.33 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-1.23 | $0.00 | $-11.59M | - |
| 2019 | $-0.85 | $215K | $-30.01M | -13955.8% |
| 2020 | $-1.99 | $231K | $-72.27M | -31287.4% |
| 2021 | $-2.79 | $1.26M | $-104.39M | -8285.2% |
| 2022 | $-2.30 | $5.73M | $-85.88M | -1499% |
| 2023 | $-1.83 | $7.88M | $-69.2M | -878.6% |
| 2024 | $-1.65 | $7.69M | $-63.12M | -820.8% |
| 2025 | $-17.85 | $7.7M | $-33.38M | -433.7% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-21.92 | $-25.27 – $-18.57 | $3M | $857.14K – $5.14M | 2 |
| 2027 | $-24.74 | $-47.71 – $-1.77 | $7M | $2M – $12M | 1 |
| 2028 | $-30.84 | $-59.48 – $-2.20 | $8M | $2.29M – $13.71M | 2 |
| 2029 | $-35.53 | $-68.52 – $-2.54 | $8M | $2.29M – $13.71M | 1 |
| 2030 | $-40.09 | $-77.32 – $-2.86 | $8M | $2.29M – $13.71M | 1 |
